Pharmacotherapy of congestive heart failure in elderly patients

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 10, Issue 2, 2005, Pages 85-94

  Burger, Peter C ^a,b   Brunner La Rocca, Hanspeter ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b HerzZentrum Bern   (Switzerland)

Author keywords

Congestive heart failure; Elderly patients; Pharmacotherapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARBAMAZEPINE; CARVEDILOL; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FOSINOPRIL; FUROSEMIDE; GLYCOPROTEIN P; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PLACEBO; PROPRANOLOL; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; STEROID; TORASEMIDE; TRANDOLAPRIL; TRICYCLIC ANTIDEPRESSANT AGENT; VALSARTAN; VASODILATOR AGENT; VERAPAMIL; WARFARIN;

ANGIONEUROTIC EDEMA; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRONCHOSPASM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG ELIMINATION; ELDERLY CARE; EXERCISE TOLERANCE; FATIGUE; FLUID RETENTION; GYNECOMASTIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INCIDENCE; KIDNEY FAILURE; LIFE EXPECTANCY; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SIDE EFFECT; STROKE; SURVIVAL RATE; TASTE DISORDER; TREATMENT OUTCOME; UREMIA;

AGED; AGING; CARDIOVASCULAR AGENTS; CLINICAL TRIALS; DRUG INTERACTIONS; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 20544478486     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840501000202     Document Type: Review

References (75)

1. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management. Am Heart J 133(6):703-712, 1997
2. Miller LW, Missov ED. Epidemiology of heart failure. Cardiol Clin 19(4):547-555, 2001
3. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 13(4):S107-112, 1994
4. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 157(1):99-104, 1997
5. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 83(2A):1A-38A, 1999
6. Cleland JG. Contemporary management of heart failure in clinical practice. Heart 88 Suppl 2:ii5-8, 2002
7. Klein L, O'Connor CM, Gattis WA, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: Review of trials and practical considerations. Am J Cardiol 91(9A):18F-40F, 2003
8. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 162(15): 1682-1688, 2002
9. Wilson JR, Reichek N, Dunkman WB, Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med 70(2):234-239, 1981
10. Patterson JH, Adams KF Jr, Applefeld MM, et al. Oral torsemide in patients with chronic congestive heart failure: Effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy 14(5): 514-521, 1994
11. Richardson A, Bayliss J, Scriven AJ, et al. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet 2(8561):709-711, 1987
12. Chow KM, Szeto CC, Wong TY, et al. Risk factors for thiazide-induced hyponatraemia. QJM 96(12):911-917, 2003
13. Chapman MD, Hanrahan R, McEwen J, Marley JE. Hyponatraemia and hypokalaemia due to indapamide. Med J Aust 176(5):219-221, 2002
14. Walma EP, Hoes AW, van Dooren C, et al. Withdrawal of long-term diuretic medication in elderly patients: A double blind randomised trial. BMJ 315(7106):464-468, 1997
15. Burr ML, King S, Davies HE, Pathy MS. The effects of discontinuing long-term diuretic therapy in the elderly. Age Ageing 6(1):38-5, 1977
16. Myers MG, Weingert ME, Fisher RH, et al. Unnecessary diuretic therapy in the elderly. Age Ageing 11(4):213-221, 1982
17. Faris R, Flather M, Purcell H, et al. Current evidence supporting the role of diuretics in heart failure: A meta analysis of randomised controlled trials. Int J Cardiol 82(2):149-158, 2002
18. Cosin J, Diez J. Torasemide in chronic heart failure: Results of the TORIC study. Eur J Heart Fail 4(4):507-513, 2002
19. Ferrara N, Del Prete M, Lombardi L, et al. Torasemide versus furosemide in patients with congestive heart failure: A double-masked, randomized study. Curr Therap Res 58(5):291-299, 1997
20. Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 63(6):525-534, 2003
21. Gurwitz JH, Avorn J, Ross-Degnan D, Lipsitz LA. Nonsteroidal anti-inflammatory drug-associated azotemia in the very old. JAMA 264(4):471-75, 1990
22. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273(18):1450-1456, 1995
23. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355(9215):1575-1581, 2000
24. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med 113(8):650-656, 2002
25. Havranek E, Abrams F, Stevens E, Parker K. Determinants of mortality in elderly patients with heart failure: The role of angiotensin-converting enzyme inhibitors. Arch Intern Med 158(18):2024-2028, 1998
26. Pulignano G, Del Sindaco D, Tavazzi L, et al. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: Data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J 143(1):45-55, 2002
27. Greenbaum R, Zucchelli P, Caspi A, et al. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br J Clin Pharmacol 49(1):23-31, 2000
28. Hoyer J, Schulte KL, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet 24(3):230-224. 1993
29. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349(9054):747-752, 1997
30. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355(9215):1582-1587, 2000
31. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345(23): 1667-1675, 2001
32. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 362(9386):767-771, 2003
33. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 362(9386):759-766, 2003
34. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344(22):1651-1658, 2001
35. Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure: Analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 38(4):932-938, 2001
36. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334(21):1349-1355, 1996
37. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 353(9146):9-13, 1999
38. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353(9169):2001-2007, 1999
39. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: Effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 3(4):469-479, 2001
40. Deedwania PC, Gottlieb S, Ghali JK, et al. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 25(15):1300-1309, 2004
41. Wikstrand J, Wedel H, Ghali J, et al. How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/ Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Card Electrophysiol Rev 7(3):264-275, 2003
42. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26(3):215-225, 2005
43. McMurray J. Making sense of SENIORS. Eur Heart J 26(3):203-206, 2005
44. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 362(9377):7-13, 2003
45. Coca SG, Buller GK. COMET: A proposed mechanism of action to explain the results and concerns about dose. Lancet 362(9389):1076; author reply 1077-1078, 2003
46. Wikstrand J, Fagerberg B, Goldstein S, et al. COMET: A proposed mechanism of action to explain the results and concerns about dose. Lancet 362(9389):1076-1077; author reply 1077-8, 2003
47. Hjalmarson A, Waagstein F. COMET: A proposed mechanism of action to explain the results and concerns about dose. Lancet 362(9389):1077; author reply 1077-1078, 2003
48. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 35(1):30-34, 1997
49. Rocha R, Chander PN, Khanna K, et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31(1 Pt 2):451-458, 1998
50. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 24(5):571-775, 1994
51. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76(17):1259-1265, 1995
52. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709-717, 1999
53. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351(6):543-551, 2004
54. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309-1321, 2003
55. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 329(1):1-7, 1993
56. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 22(4):955-962, 1993
57. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 336(8):525-533, 1997
58. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347(18):1403-1411, 2002
59. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289(7):871-878, 2003
60. Diet F, Erdmann E. Thromboembolism in heart failure: Who should be treated? Eur J Heart Fail 2(4):355-363, 2000
61. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 336(4):251-257, 1997
62. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: Evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 29(5): 1074-1080, 1997
63. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 87(6 Suppl):VI94-101, 1993
64. Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 6(4):501-508, 2004
65. Ibrahim SA, Kwoh CK. Underutilization of oral anticoagulant therapy for stroke prevention in elderly patients with heart failure. Am Heart J 140(2):219-220, 2000
66. Kitzman DW. Diastolic heart failure in the elderly. Heart Fail Rev 7(1):17-27, 2002
67. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 289(2):194-202, 2003
68. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 362(9386):777-781, 2003
69. Kitzman DW, Higginbotham MB, Cobb FR, et al. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: Failure of the Frank-Starling mechanism. J Am Coll Cardiol 17(5):1065-1072, 1991
70. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin- converting enzyme inhibitors. Am J Cardiol 80(2):207-209, 1997
71. Little WC, Wesley-Farrington DJ, Hoyle J, et al. Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunction. J Cardiovasc Pharmacol 43(2):288-293, 2004
72. Warner JG Jr, Metzger DC, Kitzman DW, et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 33(6): 1567-1572, 1999
73. Amabile CM, Spencer AP. Keeping your patient with heart failure safe: A review of potentially dangerous medications. Arch Intern Med 164(7):709-720, 2004
74. Gallagher LP, The potential for adverse drug reactions in elderly patients. Appl Nurs Res 14(4):220-224, 2001
75. Rich MW. Management of heart failure in the elderly. Heart Fail Rev 7(1):89-97, 2002